Top Story

Shorter ADT regimen improved quality of life among men with high-risk prostate cancer

September 16, 2014

Men with high-risk prostate cancer who underwent treatment with radiotherapy plus 18 months of androgen deprivation therapy demonstrated improved testosterone recovery than those who underwent radiotherapy plus 36 months of androgen deprivation, according to results of a randomized phase 3 study presented at the ASTRO Annual Meeting.

“Those who recover normal testosterone value have better quality of life,” Abdenour Nabid, MD, radiation oncologist at Centre Hospitalier Universitaire de Sherbrooke and associate professor at the University of Sherbrooke in Quebec, Canada, said during a press conference. “A higher proportion of patients [assigned 18 months of androgen deprivation therapy] recovered normal testosterone value, and they did so in a much shorter time. This was done without any apparent detriment to long-term outcomes.”

Report: Commitment to NIH, NCI funding only 'viable path' for continued success in cancer research

September 16, 2014
The scientific community’s continued quest to prevent and cure cancer has reached a crossroads, according to a report released today by the American Association…
In the Journals

AR-V7 linked to treatment resistance in castration-resistant prostate cancer

September 16, 2014
Detectable androgen receptor splice variant-7 messenger RNA in circulating tumor cells was associated with resistance to enzalutamide and abiraterone in men with…
Meeting News Coverage

High-dose radiation plus long-term ADT extended survival in prostate cancer

September 15, 2014
Men with intermediate or high-risk prostate cancer who underwent high-dose radiation therapy followed by a longer duration of androgen deprivation therapy demonstrated…
CME CNE
figure

Treatment Decision-Making through the Spectrum of MDS: Case 1 Low Risk MDS

An educational presentation from Aplastic Anemia & MDS International Foundation.

MDS is a difficult disease to diagnose and treat. Frequently it is challenging for healthcare providers to explain MDS…
More »
Meeting News Coverage Video
figure

Docetaxel plus ADT improved OS in metastatic prostate cancer

June 24, 2014
CHICAGO — Donald L. Trump, MD, FACP, president and CEO at Roswell Park Cancer Institute and HemOnc Today
More »
CME
figure

New Advances, New Options: Evaluating the Changing Landscape of Hemophilia to Optimize Patient Outcomes

This activity is supported by an educational grant from Biogen Idec.

The bleeding abnormalities associated with hemophilia can have devastating consequences for patients. Recent advances…
More »

Filter By:

Meeting News Coverage

Shorter ADT regimen improved quality of life among men with high-risk prostate cancer

September 16, 2014
Men with high-risk prostate cancer who underwent treatment with radiotherapy plus 18 months of androgen deprivation therapy demonstrated improved…

Report: Commitment to NIH, NCI funding only 'viable path' for continued success in cancer research

September 16, 2014
The scientific community’s continued quest to prevent and cure cancer has reached a crossroads, according to a report released today by the…
In the Journals

AR-V7 linked to treatment resistance in castration-resistant prostate cancer

September 16, 2014
Detectable androgen receptor splice variant-7 messenger RNA in circulating tumor cells was associated with resistance to enzalutamide and abiraterone…
Meeting News Coverage

High-dose radiation plus long-term ADT extended survival in prostate cancer

September 15, 2014
Men with intermediate or high-risk prostate cancer who underwent high-dose radiation therapy followed by a longer duration of androgen deprivation…
figure Meeting News Coverage

Toxins at Ground Zero linked with cancer among thousands of first responders

September 11, 2014
The tragedy of Sept. 11, 2001 still haunts Americans in countless ways, with many survivors continuing to struggle with the enduring grief and trauma…
Industry News

Cometriq fails to meet primary endpoint in metastatic castration-resistant prostate cancer

September 8, 2014
Results from a phase 3 trial have found that cabozantinib did not meet its primary endpoint of OS compared with prednisone for the treatment of…
In the Journals

Genomic analysis identified favorable treatment option after prostate cancer surgery

September 8, 2014
A genomic classifier may be effective in predicting the risk of biochemical failure and distant metastasis in post-surgery radiation in patients with…
In the Journals

Prostate cancer prevention trial identified behaviors linked to biopsy adherence

September 5, 2014
Among participants in the Prostate Cancer Prevention Trial, those who complied with study requirements 1 year before the end of the study were more…
In the Journals

BRCA2 mutation associated with shorter survival in screen-detected prostate cancer

September 2, 2014
Men with screen-detected prostate cancer who harbor mutations in the BRCA2 gene demonstrated poorer-than-expected prognosis, according to study…
figure In the Journals

Enzalutamide improved health-related quality of life in prostate cancer

August 26, 2014
Enzalutamide was associated with significant improvements in disease-related symptoms and all aspects of health-related quality of life among men…
More Headlines »